Erasca reported updated Phase 1 ERAS-0015 data, outlined pivotal trial plans and priced an upsized $550 million stock offering.

Erasca reported updated Phase 1 ERAS-0015 data, outlined pivotal trial plans and priced an upsized $550 million stock offering.

ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS